InMode Ltd. (NASDAQ:INMD) Receives Consensus Rating of "Hold" from Analysts

Shares of InMode Ltd. (NASDAQ:INMD - Get Free Report) have been assigned a consensus rating of "Hold" from the six research firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $32.80.

Several research firms recently weighed in on INMD. UBS Group boosted their price objective on InMode from $24.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 14th. Needham & Company LLC restated a "hold" rating on shares of InMode in a research note on Tuesday, April 9th. Finally, Barclays lowered their price target on InMode from $34.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, April 12th.

InMode Price Performance

Shares of NASDAQ INMD traded up $0.12 during trading hours on Friday, hitting $17.14. 970,055 shares of the company's stock were exchanged, compared to its average volume of 1,520,515. InMode has a 1-year low of $16.82 and a 1-year high of $48.25. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of 7.45 and a beta of 2.16. The company's 50-day moving average price is $20.32 and its 200-day moving average price is $21.49.

InMode (NASDAQ:INMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 13th. The healthcare company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. InMode had a return on equity of 29.80% and a net margin of 40.22%. The business had revenue of $126.80 million during the quarter, compared to analysts' expectations of $124.77 million. During the same quarter in the previous year, the firm earned $0.69 EPS. The firm's revenue was down 5.1% compared to the same quarter last year. On average, research analysts expect that InMode will post 2.04 earnings per share for the current year.

Institutional Investors Weigh In On InMode

Several large investors have recently modified their holdings of INMD. Exchange Traded Concepts LLC bought a new stake in shares of InMode in the 3rd quarter valued at approximately $27,000. Handelsbanken Fonder AB grew its stake in shares of InMode by 35.4% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,823 shares of the healthcare company's stock valued at $543,000 after purchasing an additional 4,662 shares during the period. Cambridge Investment Research Advisors Inc. grew its stake in shares of InMode by 32.9% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 35,018 shares of the healthcare company's stock valued at $1,067,000 after purchasing an additional 8,667 shares during the period. Dakota Wealth Management grew its stake in shares of InMode by 87.2% in the 3rd quarter. Dakota Wealth Management now owns 13,641 shares of the healthcare company's stock valued at $416,000 after purchasing an additional 6,355 shares during the period. Finally, Redwood Investments LLC grew its stake in shares of InMode by 5.4% in the 3rd quarter. Redwood Investments LLC now owns 260,663 shares of the healthcare company's stock valued at $7,940,000 after purchasing an additional 13,392 shares during the period. 68.04% of the stock is currently owned by institutional investors.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.